Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Invex founder and CEO Alex Sinclair, as well as the company’s chairman Dr Jason Loveridge.

Invex is repurposing an old diabetes drug called Exanatide to treat conditions stemming from pressure on the brain (raised intracranial pressure)

The company is tackling several potential disease treatments but it’s most advanced with its trials for Idiopathic intracranial hypertension, which can cause disabling headaches and loss of vision.

Invex was only formed in March this year and listed on the ASX in early July, raising $12m in the process.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!